California Attorney General Rob Bonta and Delaware Attorney General Kathy Jennings met with and sent an open letter to OpenAI to express their concerns over the safety of ChatGPT, particularly for children and teens. 

The warning comes a week after Bonta and 44 other attorneys general sent a letter to 12 of the top AI companies, following reports of sexually inappropriate interactions between AI chatbots and children. 

“Since the issuance of that letter, we learned of the heartbreaking death by suicide of one young Californian after he had prolonged interactions with an OpenAI chatbot, as well as a similarly disturbing murder-suicide in Connecticut,” Bonta and Jennings write. “Whatever safeguards were in place did not work.”

The two state officials are currently investigating OpenAI’s proposed restructuring into a for-profit entity to ensure that the mission of the nonprofit remains intact. That mission “includes ensuring that artificial intelligence is deployed safely” and building artificial general intelligence (AGI) to benefit all humanity, “including children,” per the letter. 

“Before we get to benefiting, we need to ensure that adequate safety measures are in place to not harm,” the letter continues. “It is our shared view that OpenAI and the industry at large are not where they need to be in ensuring safety in AI products’ development and deployment. As Attorneys General, public safety is one of our core missions. As we continue our dialogue related to OpenAI’s recapitalization plan, we must work to accelerate and amplify safety as a governing force in the future of this powerful technology.”

Bonta and Jennings have asked for more information about OpenAI’s current safety precautions and governance, and said they expect the company to take immediate remedial measures where appropriate.

TechCrunch has reached out to OpenAI for comment.

Insider Brief

• Ketryx raised $39M Series B led by Transformation Capital, with participation from Lightspeed, MIT’s E14 Fund, Ubiquity Ventures, and 53 Stations, bringing total funding to over $55M; Vinay Shah of Transformation Capital joins the board.
• Its AI-native compliance platform automates validation, traceability, and regulatory workflows (FDA/EU MDR-ready), enabling life sciences teams to achieve up to 90% faster documentation and 10x quicker release cycles without sacrificing safety.
• Already used by three of the top five global medtech companies and innovators like DeepHealth and Heartflow, Ketryx is positioning itself as the key AI infrastructure layer for regulated product development in healthcare and beyond.

Ketryx, the AI-powered compliance platform helping life sciences companies ship safer products faster, has announced a $39 million Series B led by Transformation Capital, with participation from existing investors including Lightspeed Venture Partners, MIT’s E14 Fund, Ubiquity Ventures, and 53 Stations. This latest round brings the company’s total funding to over $55 million, and Vinay Shah, Partner and Founding Team Member at Transformation Capital, will join Ketryx’s board.

Ketryx is solving one of the most difficult challenges in the life sciences: the need to accelerate product innovation without compromising safety or compliance. This challenge is more urgent than ever with teams racing to incorporate AI into regulated workflows and products.

“I’ve spent the last decade at the intersection of AI and life sciences, watching it evolve from an emerging tool to a critical application for patients,” said Erez Kaminski, CEO and founder of Ketryx. “It’s now time to accelerate adoption and ensure AI is safe, reliable, and ready for regulated environments.”

Life sciences teams are struggling to balance rigorous compliance requirements amid the rapidly accelerating pace of innovation. While cloud-based tools and rapidly evolving LLMs are transforming what’s possible, these regulated teams are still operating on infrastructure not designed for this velocity of change.

Ketryx is an AI-native compliance platform built to meet this challenge. It automates validation, traceability, and regulatory workflows — including FDA/EU MDR-ready documentation — across the product development lifecycle to help teams release safer products faster. Customers report up to a 90% reduction in documentation time and over 10x faster release cycles.

“In Medtech, long-term success depends on balancing innovation with the uncompromising demands of safety and compliance,” said Bill Hawkins, former CEO of Medtronic and new Ketryx investor. “This balance has historically been hard to achieve. Ketryx has built the infrastructure that allows both to advance together. Their ability to deliver this level of rigor at true enterprise scale is why I’m proud to support them as they shape the future of regulated software.”

The company’s platform is built for the enterprise and already used by three of the top five global medtech companies, several Fortune 500 organizations, and AI-powered companies such as DeepHealth, Heartflow, and Aignostics. With adoption accelerating, Ketryx is emerging as the key AI infrastructure layer for product development in regulated industries.

“Medtech teams are leading the way in applying artificial intelligence to improve patient outcomes, creating products that meet the highest safety and regulatory standards,” said Vinay Shah, Partner and Founding Team Member at Transformation Capital. “In our diligence, Fortune 500 giants and fast-growing innovators consistently praised Ketryx for proving that compliance can accelerate, rather than slow, technological progress. We believe Ketryx is defining the future of regulated infrastructure across industries and are proud to back them in their next stage of growth.”

Kaminski continued, “Having Transformation Capital, the pre-eminent digital health VC & growth equity firm, as our lead partner, gives us more than just capital. They understand exactly what it takes to build and scale healthcare technology companies. With their backing and industry connections, we’re continuing our global expansion, accelerating our product roadmap, and hiring rapidly in both Boston and Austria.”

With real-time traceability and documentation, Ketryx brings zero-lag compliance to the heart of product development, empowering teams to release more products, more safely, and faster than ever before.

About Ketryx
Ketryx transforms the product lifecycle of life science teams to deliver safer products, faster. Trusted by three of the world’s top five medical device manufacturers, its AI-powered compliance platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles — without disrupting existing workflows. Ketryx AI Agents cut manual work by 90 percent and close compliance gaps, elevating speed and quality across the entire product lifecycle. For more information, visit www.ketryx.com.

SOURCE

Broadcom Inc. is helping OpenAI design and produce an artificial intelligence accelerator from 2026, getting into a lucrative sphere dominated by Nvidia Corp. Its shares jumped by the most since April.

The two firms plan to ship the first chips in that lineup starting next year, a person familiar with the matter said, asking to remain anonymous discussing a private deal. OpenAI will initially use the chip for its own internal purposes, the Financial Times reported earlier.

Broadcom’s shares surged as much as 16% in New York trading on Friday, adding more than $200 billion to the company’s market value. Nvidia’s stock was down as much as 4.3% at $164.22, its biggest intraday decline since May.

Chief Executive Officer Hock Tan made veiled references to that partnership on Thursday when he said Broadcom had secured a new client for its custom accelerator business. Tan said the company has secured more than $10 billion in orders from the new customer, which the person identified as OpenAI.

Accelerators are essential to the development of AI at big tech firms from Meta Platforms Inc. to Microsoft Corp. Bloomberg News has previously reported that OpenAI and Broadcom were working on an inference chip design, intended to run or operate artificial intelligence services after they had been trained.

“Last quarter, one of these prospects released production orders to Broadcom,” Tan said, without naming the customer.

Broadcom is among the chip designers benefiting from a post-ChatGPT boom in AI development, in which companies and startups from the US to China are spending billions to build data centers, train new models and research breakthroughs in a pivotal new technology. On Thursday, Tan told investors the chipmaker’s outlook will improve “significantly” in fiscal 2026, helping allay concerns about slowing growth.

Tan had previously said that AI revenue for 2026 would show growth similar to the current year — a rate of 50% to 60%. Now, with a new customer that he said has “immediate and pretty substantial demand,” the rate will accelerate in a way that will be “fairly material,” Tan said.

“We now expect the outlook for fiscal 2026 AI revenue to improve significantly from what we had indicated last quarter,” he said.

Broadcom’s quarterly results initially drew a tepid reaction from investors, a sign they were anticipating a bigger payoff from the AI boom. After fluctuating in the wake of the report, the stock gained more than 3% during the conference call.

Sales will be about $17.4 billion in the fiscal fourth quarter, which runs through October, the company said in an earlier statement. Analysts had projected $17.05 billion on average, though some estimates topped $18 billion, according to data compiled by Bloomberg.

Expectations were high heading into the earnings report. Broadcom shares more than doubled since hitting a low in April, adding about $730 billion to the company’s market value and making them the third-best performer in the Nasdaq 100 Index.

Investors have been looking for signs that tech spending remains strong. Last week, Nvidia gave an underwhelming revenue forecast, sparking fears of a bubble in the artificial intelligence industry.

Though Broadcom hasn’t experienced Nvidia’s runaway sales growth, it is seen as a key AI beneficiary. Customers developing and running artificial intelligence models rely on its custom-designed chips and networking equipment to handle the load. The shares had been up 32% for the year.

During the call, Tan said he and the board have agreed that he will stay as Broadcom CEO until 2030 “at least.”

In the third quarter ended Aug. 3, sales rose 22% to almost $16 billion. Profit, excluding some items, was $1.69 a share. Analysts had estimated revenue of about $15.8 billion and earnings of $1.67 a share.

Sales of AI semiconductors were $5.2 billion, compared with an estimate of $5.11 billion. The company expects revenue from that category to reach $6.2 billion in the fourth quarter. Analysts projected $5.82 billion.

Other AI-focused chipmakers have stumbled in recent days. Shares of Marvell Technology Inc., a close Broadcom competitor in the market for custom semiconductors, plunged 19% on Friday after the company’s data center revenue missed estimates.

Broadcom’s Tan has been upgrading the company’s networking equipment to better transfer information between the pricey graphics chips at the heart of AI data centers. As his latest comments suggest, Broadcom is also making progress finding customers who want custom-designed chips for AI tasks.

Tan has used years of acquisitions to turn Broadcom into a sprawling software and hardware giant. In addition to the AI work, the Palo Alto, California-based company makes connectivity components for Apple Inc.’s iPhone and sells virtualization software for running networks.

Bass writes for Bloomberg.